Remicade Archives -

From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an

3 key trends shaping the immunology market

https://pharmaphorum.com/views-analysis-market-access/3-key-trends-shaping-the-immunology-market/

Johnson & Johnson’s antibody blockbuster Remicade has proved highly resistant to biosimilar competition – so much so that

J&J faces FTC probe on Remicade biosimilar defence

https://pharmaphorum.com/news/jj-faces-ftc-probe-on-remicade-biosimilar-defence/

Johnson & Johnson (J&J) has kicked off results season with a downbeat forecast for the year as competition

J&J ends 2018 on a high, but coming year looks shaky

https://pharmaphorum.com/news/jj-ends-2018-on-a-high-but-coming-year-looks-shaky/

New use for patients who fail anti-TNF drugs

Stelara gains US approval for Crohn’s disease

https://pharmaphorum.com/news/stelara-crohns/

Pfizer must wait until 180 day period ends, court fight ongoing.

No US Remicade biosimilar until at least October

https://pharmaphorum.com/news/no-us-remicade-biosimilar-until-at-least-october/

Antibodies against originator will also target biosimilar.

Biosimilar switching not suitable for all patients

https://pharmaphorum.com/news/biosimilar-switching-not-suitable-patients/

Remicade